KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) Times Interest Earned (2017 - 2025)

Arbutus Biopharma's Times Interest Earned history spans 9 years, with the latest figure at -$376.48 for Q3 2025.

  • For Q3 2025, Times Interest Earned rose 49.08% year-over-year to -$376.48; the TTM value through Sep 2025 reached -$429.39, up 22.01%, while the annual FY2024 figure was -$557.07, 227.38% down from the prior year.
  • Times Interest Earned for Q3 2025 was -$376.48 at Arbutus Biopharma, down from $53.14 in the prior quarter.
  • Across five years, Times Interest Earned topped out at $53.14 in Q2 2025 and bottomed at -$917.82 in Q1 2025.
  • The 5-year median for Times Interest Earned is -$87.94 (2023), against an average of -$259.31.
  • The largest annual shift saw Times Interest Earned crashed 1028.81% in 2023 before it soared 108.37% in 2025.
  • A 5-year view of Times Interest Earned shows it stood at -$37.14 in 2021, then plummeted by 96.62% to -$73.02 in 2022, then plummeted by 545.78% to -$471.52 in 2023, then increased by 1.5% to -$464.43 in 2024, then rose by 18.94% to -$376.48 in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Times Interest Earned are -$376.48 (Q3 2025), $53.14 (Q2 2025), and -$917.82 (Q1 2025).